Document Detail

Plasma levels of natriuretic peptides and hemodynamic assessment of patent ductus arteriosus in preterm infants.
MedLine Citation:
PMID:  11236049     Owner:  NLM     Status:  MEDLINE    
The main purpose of this study was to investigate whether circulating natriuretic peptides in premature infants reflect the hemodynamic significance of a patent ductus arteriosus (PDA). The study comprises 120 examinations in 55 premature infants with a mean gestational age of 27.2 wk and a mean birthweight of 933 g. Based on clinical and echocardiographic findings, the hemodynamic influence of ductal shunting was classified as small, moderate or large. Blood samples for N-terminal proatrial natriuretic peptide (Nt-proANP) and brain natriuretic peptide (BNP) were analysed after completion of the clinical part of the study. Linear regression indicated a very strong association between Nt-proANP and BNP (adjusted R = 0.89). The mean levels of Nt-proANP and BNP increased with the size of the shunt through a PDA, and peptide values followed hemodynamic alterations. The size of PDA accounted for 50% and 47% of the total variation in the plasma values of Nt-proANP and BNP, respectively. In detecting an echocardiographically significant PDA, the area under a ROC curve was 0.94 for Nt-proANP and 0.90 for BNP. Conclusion: The magnitude of shunting through a PDA is the main determinant of plasma levels of natriuretic peptides in premature infants. Nt-proANP and BNP seem to have the same pattern of secretion. Our findings indicate that measurements of natriuretic peptides may provide clinically relevant information in the hemodynamic assessment of premature infants.
H Holmström; C Hall; E Thaulow
Related Documents :
15708459 - Cerebral hemodynamic change and intraventricular hemorrhage in very low birth weight in...
20814479 - Hybrid management of a large atrial septal defect and a patent ductus arteriosus in an ...
19626809 - Short-term outcome of pda ligation in the preterm infants at king chulalongkorn memoria...
2643499 - Pharmacologic management of patent ductus arteriosus.
15678229 - Trisomy 21 and congenital heart disease: effect of timing of initial echocardiogram.
9482139 - Role of left ventricular mass/volume ratio on transmitral flow velocity patterns from i...
21673719 - Modifying effect of maternal nutritional status on the impact of maternal multiple micr...
1995389 - The relationship between apgar score, umbilical artery ph and operative delivery for fe...
20444809 - Accuracy of amplitude integrated eeg in a neonatal cohort.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Acta paediatrica (Oslo, Norway : 1992)     Volume:  90     ISSN:  0803-5253     ISO Abbreviation:  Acta Paediatr.     Publication Date:  2001 Feb 
Date Detail:
Created Date:  2001-03-08     Completed Date:  2001-07-12     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9205968     Medline TA:  Acta Paediatr     Country:  Norway    
Other Details:
Languages:  eng     Pagination:  184-91     Citation Subset:  IM    
Department of Pediatrics, National Hospital, Rikshospitalet, Oslo, Norway.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Atrial Natriuretic Factor / blood*
Ductus Arteriosus, Patent / diagnosis*,  therapy
Hemodynamics / physiology
Infant, Newborn
Infant, Premature
Regression Analysis
Reg. No./Substance:
85637-73-6/Atrial Natriuretic Factor
Comment In:
Acta Paediatr. 2001 Apr;90(4):363-5   [PMID:  11332921 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Detection of bacterial DNA by PCR and reverse hybridization in the 16S rRNA gene with particular ref...
Next Document:  Patent ductus venosus does not lead to alimentary galactosaemia in preterm infants.